Shanghai Kaibao Pharmaceutical CO.,Ltd (SHE:300039)

Market Cap	5.99B -5.1%
Revenue (ttm)	1.04B -26.0%
Net Income	259.16M -30.2%
EPS	0.25 -30.2%
Shares Out	1.05B
PE Ratio	23.13
Forward PE	n/a
Dividend	0.06 (1.05%)
Ex-Dividend Date	Nov 27, 2025

Volume	10,111,683
Average Volume	9,374,192
Open	5.59
Previous Close	5.73
Day's Range	5.59 - 5.79
52-Week Range	5.55 - 7.03
Beta	0.39
RSI	46.89
Earnings Date	Apr 28, 2026

About SHE:300039

Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern Chinese medicines primarily in China. Its primary products include Tanreqing injection for the treatment of pneumonia, acute and chronic bronchitis, and upper respiratory tract infection; Tanreqing capsules that clears heat and detoxifies and removes phlegm; tiopronin for injection, which improves liver function of various acute and chronic hepatitis; Tiopronin enteric-coated tablets for adjuvant treatment of chronic hepatitis; and Xiongd...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 1,225
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300039

Financial Performance

In 2025, SHE:300039's revenue was 1.15 billion, a decrease of -21.76% compared to the previous year's 1.47 billion. Earnings were 278.58 million, a decrease of -25.83%.